NCT02500849进行中（未招募）1 期
A Pilot Study to Evaluate the Feasibility, Safety and Engraftment of Zinc Finger Nuclease (ZFN) CCR5 Modified CD34+ Hematopoietic Stem/Progenitor Cells (SB-728mR-HSPC) in HIV-1 (R5) Infected Patients
City of Hope Medical Center10 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2016年3月10日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 12
- 试验地点
- 10
- 主要终点
- Toxicity in subjects who received SB-728mR-HSPC after each busulfan dose level
研究概览
简要总结
The purpose of the study is to evaluate the safety and feasibility of administering SB-728mR-HSPC after conditioning with busulfan.
详细描述
The objective of the study is to evaluate the safety and feasibility of giving autologous SB-728mR-HSPC to HIV-1 (R5) infected patients who are being treated with cART and have undetectable virus but suboptimal CD4+ cell levels. To strengthen the possibility that CCR5-disrupted HSPCs engraft, patients will receive either a two- or three-day (Cohort 1 or Cohort 2) course of busulfan (dose targeting AUC of 4000 µM/day) before being infused with the genetically modified cells. At 9-12 months after SB-728mR-HSPC infusion, subjects who are aviremic with CD4 cell counts ≥600 cells/µL and have ≥1% CCR5-modified CD4 cells within the peripheral blood detected by pentamer PCR will undergo an ATI.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Maximum age 75 years for cohort 1 and 65 years for cohort
- •HIV-1 R5 seropositive with no evidence of CXCR4-tropic virus.
- •On cART with undetectable HIV-1 (<20 gc/ml HIV-1 RNA) for at least 12 months prior to screening evaluations.
- •CD4+ T-cell counts ≥200 cells/µL and ≤750 cells/µL.
- •No psychosocial conditions that would hinder study compliance and follow-up.
- •Absence of clinically significant cardiomyopathy, congestive heart failure.
- •Secondary Eligibility Criteria (for registration):
- •Complete G-CSF/Plerixafor mobilization of HSPC.
- •Collect ≥7.5 x 10^6 CD34+ cells/kg in two aphereses.
- •The SB-728mR-HSPC product passed all release testing
排除标准
- •Use of AZT or maraviroc in the cART regimen.
- •History of significant hematologic diseases such as leukemia, myelodysplasia, coagulopathy, and thromboembolism.
- •Any AIDS-related opportunistic infection occurring within the past year such as tuberculosis, cryptococcosis and for which treatment has been unsuccessful as determined by the Principal Investigator.
- •AIDS-related syndromes, infectious or otherwise, if perceived to cause excessive risk for morbidity post-HSPC infusion, as determined by the Principal Investigator.
- •Patients with active HBV or HCV infection, i.e., HBV DNA and HCV RNA in blood, are excluded. Those with inactive, but past infection with HBV (positive HBV surface antigen or HBV surface antibody) or inactive HCV (positive HCV antibody), must have no cirrhosis, as determined by abdominal ultrasound with elastography.
- •Active CMV retinitis or other active CMV-related organ dysfunction.
- •CXCR4-tropic virus.
- •Pregnant or nursing women.
- •Any history of HIV-associated encephalopathy; dementia of any kind; seizures in the past 12 months; any perceived inability to directly provide informed consent.
- •Participants may not be receiving any other investigational agents, or concurrent biological, chemotherapy, or radiation therapy. Participation in prior investigational drug or medical device study within the previous 45 days.
- •Current or history of immunomodulatory agent or steroid use.
- •Prior therapy with HIV vaccine or gene therapy product.
- •History of alcohol or substance abuse for the previous 12 months.
- •Participants with active malignancies. However, participants with skin cancers, namely basal cell or squamous cell carcinoma, and malignancies treated with curative intent having no known active disease present for ≥2 years, may be eligible.
结局指标
主要结局
Toxicity in subjects who received SB-728mR-HSPC after each busulfan dose level
时间窗: 18 months
次要结局
- Number of CD34+ HSPC collected, gene modified, and released throughout the manufacturing process(Approximately first 1-2 months on study)
研究者
研究点 (10)
Loading locations...
相似试验
尚未招募
不适用
Utilizing Carbon Dioxide for Assessing Coronary Blood Flow in Subjects With Coronary Artery DiseaseCoronary Artery DiseaseNCT06253884Indiana University30
撤回
2 期
A Pilot Study of HP802-247 in Dystrophic Epidermolysis BullosaDystrophic Epidermolysis BullosaNCT01528306Healthpoint
已完成
不适用
Light Therapy for Onychomycosis StudyOnychomycosis of ToenailNCT05139888ToeFX Inc.126
尚未招募
2 期
A pilot study to evaluate the feasibility, safety and tolerability of neoadjuvant triple therapy with zoledronic acid, docetaxel, and luteinising hormone-releasing hormone (LH-RH) analogue for men with high-risk prostate cancer to be treated by radical prostatectomyCancer - ProstateProstate cancerACTRN12607000082404rology Department The Royal Melbourne Hospital15
招募中
不适用
A pilot study of psychotherapeutic intervention for complex presentations of first-episode psychosisEarly psychosisMental Health - Psychosis and personality disordersBorderline Personality DisorderACTRN12605000594628Orygen Research Centre and Orygen Youth Health16